



Name	Byung-Su Kim, MD, PhD	
Current Position	Clinical Professor, Eunpyeong St. Mary's Hospital, Hematology, Catholic University of Korea, South Korea	
Country	South Korea	
Major Field	Lymphoid Malignancies GVHD Immuno-Oncology	

Educational Background

- **M.D.** Seoul National University, College of Medicine, South Korea
- **M.S.** Seoul National University, College of Medicine, South Korea
- **Ph.D.** Seoul National University, College of Medicine, South Korea

Professional Experience

- **Postdoc Scholar** Med/BMT, School of Medicine, Stanford University, USA
- **Clinical assistant professor** Hemato-Oncology, Seoul Metropolitan Boramae Hospital, Seoul National University, South Korea
- **Associate professor** Hemato-Oncology, Dongtan Sacred Heart Hospital, Hallym University, South Korea

Other Experience and Professional Memberships

Main Scientific Publications

1. **Kim BS***, Nishikii H*, Baker J, Pierini A, et al. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease. **Blood**. 2015

Jul 23;126(4):546-57. (*equal contribution)

2. Nishikii H*, Kim BS*, Yokoyama Y, et al. DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease. **Blood. 2016 Dec 15;128(24):2846-2858. (*equal contribution)**

3. Ronald J*, Kim BS*, Gowrishankar G, et al. A Positron Emission Tomography Strategy for Visualizing Activated T Cells in Acute Graft-Versus-Host Disease. **Cancer Res. 2017 June 1; 77(11):2893-2902. (*equal contribution)**

4. Lim JY, Kim BS, Ryu DB, et al. The therapeutic efficacy of mesenchymal stromal cells on experimental colitis was improved by the IFN- γ and poly(I:C) priming through promoting the expression of indoleamine 2,3-dioxygenase. **Stem Cell Res Ther. 2021 Jan 7;12(1):37.**

(Corresponding Author)
